Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
In this study, a cohort of patients with newly diagnosed CLL was followed to identify the incidence of SCC skin cancer and its associated risk factors in this population.
Hydrochlorothiazide is indicated for the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.
This retrospective study suggests that patients with prior ipilimumab-related adverse events related can safely retry anti–PD-1 therapy.
It was determined that ICIs were less efficacious in Taiwanese patients with melanoma.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
This study used data from the Nurses’ Health Study (NHS) and NHS2 to explore the association between height, number of nevi, and risk of invasive melanoma.
Because the TNF-α pathway plays a critical role in tumor surveillance, there is concern that inhibition of this pathway could predispose patients to certain malignancies.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Time from diagnosis to definitive surgery is twice as long on average for black versus white patients.
Most studies that have looked at 31-GEP testing in melanoma have been retrospective or prospective, and did not involve a comparator group.
A small phase 1/2 study shows high pCR rates.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Previous studies have shown an association between gut microbiome diversity and response to immune checkpoint inhibitor therapy.
Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.
Atezolizumab plus cobimetinib and vemurafenib prolonged PFS in unresectable or metastatic melanoma compared with placebo and BRAF/MEK inhibition in the phase 3 IMspire150 trial.
Although allogeneic HCT is associated with increased risk for keratinocyte carcinoma, the magnitude of risk linked to certain patient characteristics is still unknown.
There was no increase in survival linked to acquired subclinical thyroid dysfunction or preexisting thyroid dysfunction, however.
Imaging radiomics and blood markers could differentiate pseudoprogression.